Geriatric Assessments in Elderly Diffuse Large B-cell Lymphoma Patients-2 (GERIAD2)
Completed
- Conditions
- Lymphoma, Large B-cell, Diffuse
- Registration Number
- NCT03211702
- Lead Sponsor
- Chonbuk National University Hospital
- Brief Summary
This study will validate the impact of comprehensive geriatric assessments using activity of daily living (ADL), instrumental activity of daily living (IADL), and Charlson's comorbidity index (CCI) on survival and toxicities in Korean patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
- Patients with newly diagnosed CD20+ DLBCL
- 65 years old or over
- Scheduled to receive R-CHOP chemotherapy
- Informed consent
Exclusion Criteria
- Other histology than CD20+ DLBCL
- Primary central nervous system DLBCL
- Patients with a diagnosis of cancer (other than basal or squamous cell carcinoma of the skin, cervical carcinoma in situ, well differentiated thyroid cancer [papillary or follicular thyroid cancer]) within 3 years before the study entry or with any treatment for cancer within 3 years before entry
- Consent withdrawal
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Event-free survival 2 years Event-free survival was defined as death, relapse from complete remission, progression during or after treatment, and discontinuation or changes of therapy during treatments
- Secondary Outcome Measures
Name Time Method Cumulative incidence of grade 3/4 adverse events and premature treatment discontinuation 1 year Overall survival 5 years Progression-free survival 5 years
Trial Locations
- Locations (2)
Chonnam National University Hwasun Hospital
🇰🇷Hwasun, Korea, Republic of
Chonbuk National University Hospital
🇰🇷Jeonju, Korea, Republic of